Actively Recruiting

Age: 18Years - 100Years
All Genders
ID05344469

A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate, and Interferon 2) and Oral Treatments (Teriflunomide, Dimethyl Fumarate, and Diroximel Fumarate) in Patients With Relapsing Multiple Sclerosis [AIOLOS]

Led by Novartis Pharmaceuticals · Updated on 2026-06-01

800

Participants Needed

129

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to observe patients with relapsing multiple sclerosis (RMS) who are being treated with approved injectable or selected oral disease-modifying therapies (DMTs) in Germany. The study collects data to understand how these treatments are used in routine care and their effects over time. It is an observational, non-interventional, multicenter, open-label study sponsored by Novartis Pharmaceuticals. Patients will be followed in two cohorts: Cohort 1 includes patients starting or recently started on injectable DMTs, and Cohort 2 includes patients starting or recently started on either ofatumumab or other approved injectable or oral DMTs. The core observational period is up to two years, with an optional extension adding another two years, totaling up to about four years of observation. Treatment decisions are made independently by patients and their physicians, and no study-mandated treatment or monitoring is imposed. Participants will provide data through questionnaires and electronic case report forms, with medical history including disease duration, lab values, MRI results, and relapse information collected. Routine clinical care assessments and telemedicine visits may occur at the investigator's discretion. The study measures include treatment continuation rates, disability scores, relapse rates, quality of life, fatigue, anxiety, depression, MRI lesion monitoring, and safety events, with follow-up visits scheduled as per standard care over the study period.

CONDITIONS

Brief Title

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent before participation
  • Male or female patients aged 18 years or older at enrollment
  • Diagnosis of multiple sclerosis according to the 2017 or 2024 revised McDonald criteria
  • Relapsing multiple sclerosis with active disease as defined by Lublin et al. (2014)
  • No more than 1 relapse in the past year and no more than 2 relapses in the past two years
  • Disability status with an EDSS score from 0 to 2.5 (Cohort 1) or 0 to 3.0 (Cohort 2)
  • Planned start or start within 14 days of an approved injectable or oral disease-modifying therapy for MS as routine treatment
  • For Cohort 2: ofatumumab patients must be treatment-naive or previously treated with a maximum of one other DMT, and patients on other listed treatments must be treatment-naive
Not Eligible

You will not qualify if you...

  • Treatment outside the approved label
  • More than 5 years since first symptom leading to MS diagnosis at enrollment
  • Previous therapy with any DMT for MS prior to enrollment except within 14 days for Cohort 1
  • Severe relapse before enrollment causing significant daily life deficits
  • Poor recovery from first two relapses before enrollment
  • EDSS Functional System Score "Pyramidal Functions" of 2 or higher at enrollment
  • Simultaneous participation in any investigational trial or another Novartis-sponsored non-interventional study with ofatumumab
  • Previous enrollment in Cohort 1 (for Cohort 2 only)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person or telemedicine) for consent and eligibility confirmation

Long-term Monitoring

Duration - Up to approximately 2 years (with possible extension to 4 years for some participants)

Participants who have decided with their physician to start an approved injectable or oral treatment for relapsing multiple sclerosis as routine care are observed over time. Data collection includes health status, treatment retention, questionnaires, and clinical assessments according to routine medical practice and investigator discretion.

Visits occur at investigator's discretion, including baseline and follow-up assessments approximately every 3 to 6 months

Trial Site Locations

Total: 129 locations

1

Novartis Investigative Site

Albstadt, Baden-Wurttemberg, Germany, 72458

Actively Recruiting

2

Novartis Investigative Site

Hettingen, Baden-Wurttemberg, Germany, 72513

Completed

3

Novartis Investigative Site

Hettingen, Baden-Wurttemberg, Germany, 72513

Actively Recruiting

4

Novartis Investigative Site

Mannheim, Baden-Wurttemberg, Germany, 68163

Actively Recruiting

5

Novartis Investigative Site

Nagold, Baden-Wurttemberg, Germany, 72202

Actively Recruiting

6

Novartis Investigative Site

Schwäbisch Hall, Baden-Wurttemberg, Germany, 74523

Actively Recruiting

7

Novartis Investigative Site

Schwetzingen, Baden-Wurttemberg, Germany, 68723

Actively Recruiting

8

Novartis Investigative Site

Bamberg, Bavaria, Germany, 96052

Active, Not Recruiting

9

Novartis Investigative Site

Dillingen an der Donau, Bavaria, Germany, 89407

Active, Not Recruiting

10

Novartis Investigative Site

Munich, Bavaria, Germany, 81241

Withdrawn

11

Novartis Investigative Site

Munich, Bavaria, Germany, 81829

Withdrawn

12

Novartis Investigative Site

Neuburg A.d. Donau, Bavaria, Germany, 86633

Active, Not Recruiting

13

Novartis Investigative Site

Regensburg, Bavaria, Germany, 93059

Withdrawn

14

Novartis Investigative Site

Unterhaching, Bavaria, Germany, 82008

Active, Not Recruiting

15

Novartis Investigative Site

Untermeitingen, Bavaria, Germany, 86836

Actively Recruiting

16

Novartis Investigative Site

Wolfratshausen, Bavaria, Germany, 82515

Withdrawn

17

Novartis Investigative Site

Falkensee, Brandenburg, Germany, 14612

Withdrawn

18

Novartis Investigative Site

Bad Homburg, Hesse, Germany, 61348

Actively Recruiting

19

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany, 60313

Completed

20

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany, 65929

Active, Not Recruiting

21

Novartis Investigative Site

Marburg, Hesse, Germany, 35043

Active, Not Recruiting

22

Novartis Investigative Site

Hanover, Lower Saxony, Germany, 30161

Active, Not Recruiting

23

Novartis Investigative Site

Hanover, Lower Saxony, Germany, 30449

Active, Not Recruiting

24

Novartis Investigative Site

Wildeshausen, Lower Saxony, Germany, 27793

Active, Not Recruiting

25

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany, 50935

Actively Recruiting

26

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany, 51063

Withdrawn

27

Novartis Investigative Site

Dortmund, North Rhine-Westphalia, Germany, 44135

Actively Recruiting

28

Novartis Investigative Site

Dortmund, North Rhine-Westphalia, Germany, 44287

Actively Recruiting

29

Novartis Investigative Site

Düsseldorf, North Rhine-Westphalia, Germany, 40225

Actively Recruiting

30

Novartis Investigative Site

Essen, North Rhine-Westphalia, Germany, 45134

Withdrawn

31

Novartis Investigative Site

Gelsenkirchen, North Rhine-Westphalia, Germany, 45894

Actively Recruiting

32

Novartis Investigative Site

Meerbusch, North Rhine-Westphalia, Germany, 40667

Actively Recruiting

33

Novartis Investigative Site

Münster, North Rhine-Westphalia, Germany, 48165

Withdrawn

34

Novartis Investigative Site

Oer-Erkenschwick, North Rhine-Westphalia, Germany, 45739

Withdrawn

35

Novartis Investigative Site

Ingelheim, Rhineland-Palatinate, Germany, 55218

Withdrawn

36

Novartis Investigative Site

Saarlouis, Saarland, Germany, 66740

Withdrawn

37

Novartis Investigative Site

Chemnitz, Saxony, Germany, 09117

Active, Not Recruiting

38

Novartis Investigative Site

Dresden, Saxony, Germany, 01307

Actively Recruiting

39

Novartis Investigative Site

Leipzig, Saxony, Germany, 04103

Completed

40

Novartis Investigative Site

Leipzig, Saxony, Germany, 04315

Active, Not Recruiting

41

Novartis Investigative Site

Altmark, Saxony-Anhalt, Germany, 39629

Withdrawn

42

Novartis Investigative Site

Halle, Saxony-Anhalt, Germany, 06120

Actively Recruiting

43

Novartis Investigative Site

Altenburg, Thuringia, Germany, 04600

Completed

44

Novartis Investigative Site

Altenburg, Thuringia, Germany, 04600

Withdrawn

45

Novartis Investigative Site

Jena, Thuringia, Germany, 07740

Actively Recruiting

46

Novartis Investigative Site

Mühlhausen, Thuringia, Germany, 99974

Actively Recruiting

47

Novartis Investigative Site

Altenholz, Germany, 24161

Actively Recruiting

48

Novartis Investigative Site

Alzey, Germany, 55232

Withdrawn

49

Novartis Investigative Site

Bamberg, Germany, 96047

Active, Not Recruiting

50

Novartis Investigative Site

Bayreuth, Germany, 95445

Active, Not Recruiting

51

Novartis Investigative Site

Bergneustadt, Germany, 51702

Withdrawn

52

Novartis Investigative Site

Bergneustadt, Germany, 51702

Actively Recruiting

53

Novartis Investigative Site

Berlin, Germany, 10437

Active, Not Recruiting

54

Novartis Investigative Site

Berlin, Germany, 10713

Active, Not Recruiting

55

Novartis Investigative Site

Berlin, Germany, 12099

Actively Recruiting

56

Novartis Investigative Site

Berlin, Germany, 12099

Active, Not Recruiting

57

Novartis Investigative Site

Berlin, Germany, 12099

Completed

58

Novartis Investigative Site

Berlin, Germany, 12163

Actively Recruiting

59

Novartis Investigative Site

Berlin, Germany, 12351

Completed

60

Novartis Investigative Site

Berlin, Germany, 13357

Withdrawn

61

Novartis Investigative Site

Berlin, Germany, 14169

Active, Not Recruiting

62

Novartis Investigative Site

Bochum, Germany, 44787

Actively Recruiting

63

Novartis Investigative Site

Bochum, Germany, 44791

Actively Recruiting

64

Novartis Investigative Site

Bonn, Germany, 53111

Actively Recruiting

65

Novartis Investigative Site

Böblingen, Germany, 71032

Actively Recruiting

66

Novartis Investigative Site

Braunschweig, Germany, 38100

Actively Recruiting

67

Novartis Investigative Site

Bremen, Germany, 28195

Active, Not Recruiting

68

Novartis Investigative Site

Chemnitz, Germany, 09117

Actively Recruiting

69

Novartis Investigative Site

Coburg, Germany, 96450

Actively Recruiting

70

Novartis Investigative Site

Crailsheim, Germany, 74564

Actively Recruiting

71

Novartis Investigative Site

Dessau, Germany, 06846

Actively Recruiting

72

Novartis Investigative Site

Dresden, Germany, 01067

Active, Not Recruiting

73

Novartis Investigative Site

Dresden, Germany, 01097

Actively Recruiting

74

Novartis Investigative Site

Duisburg, Germany, 47138

Withdrawn

75

Novartis Investigative Site

Düsseldorf, Germany, 40211

Completed

76

Novartis Investigative Site

Düsseldorf, Germany, 40211

Actively Recruiting

77

Novartis Investigative Site

Düsseldorf, Germany, 40625

Actively Recruiting

78

Novartis Investigative Site

Eisleben Lutherstadt, Germany, 06295

Actively Recruiting

79

Novartis Investigative Site

Eltville, Germany, 65343

Actively Recruiting

80

Novartis Investigative Site

Erbach im Odenwald, Germany, 64711

Actively Recruiting

81

Novartis Investigative Site

Erfurt, Germany, 99096

Actively Recruiting

82

Novartis Investigative Site

Erfurt, Germany, 99099

Actively Recruiting

83

Novartis Investigative Site

Erlangen, Germany, 91054

Actively Recruiting

84

Novartis Investigative Site

Essen, Germany, 45138

Actively Recruiting

85

Novartis Investigative Site

Essen, Germany, 45257

Actively Recruiting

86

Novartis Investigative Site

Fulda, Germany, 36037

Completed

87

Novartis Investigative Site

Fulda, Germany, 36037

Actively Recruiting

88

Novartis Investigative Site

Giessen, Germany, 35392

Actively Recruiting

89

Novartis Investigative Site

Gladenbach, Germany, 35075

Actively Recruiting

90

Novartis Investigative Site

Hagen, Germany, 58095

Active, Not Recruiting

91

Novartis Investigative Site

Hamburg, Germany, 20249

Actively Recruiting

92

Novartis Investigative Site

Hamburg, Germany, 22179

Actively Recruiting

93

Novartis Investigative Site

Hanover, Germany, 30625

Actively Recruiting

94

Novartis Investigative Site

Höxter, Germany, 37671

Actively Recruiting

95

Novartis Investigative Site

Itzehoe, Germany, 25524

Withdrawn

96

Novartis Investigative Site

Kaiserslautern, Germany, 67655

Actively Recruiting

97

Novartis Investigative Site

Karlsruhe, Germany, 76133

Withdrawn

98

Novartis Investigative Site

Lünen, Germany, 44534

Withdrawn

99

Novartis Investigative Site

Magdeburg, Germany, 39104

Actively Recruiting

100

Novartis Investigative Site

Marburg, Germany, 35037

Completed

101

Novartis Investigative Site

Mettmann, Germany, 40822

Completed

102

Novartis Investigative Site

Minden, Germany, 32429

Completed

103

Novartis Investigative Site

Montabaur, Germany, 56410

Completed

104

Novartis Investigative Site

Mülheim, Germany, 45468

Withdrawn

105

Novartis Investigative Site

München, Germany, 80939

Actively Recruiting

106

Novartis Investigative Site

München, Germany, 81675

Active, Not Recruiting

107

Novartis Investigative Site

Münster, Germany, 48149

Actively Recruiting

108

Novartis Investigative Site

Neuruppin, Germany, 16816

Active, Not Recruiting

109

Novartis Investigative Site

Nuremberg, Germany, 90491

Withdrawn

110

Novartis Investigative Site

Osnabrück, Germany, 49074

Actively Recruiting

111

Novartis Investigative Site

Pforzheim, Germany, 75172

Actively Recruiting

112

Novartis Investigative Site

Potsdam, Germany, 14471

Actively Recruiting

113

Novartis Investigative Site

Remscheid, Germany, 42853

Actively Recruiting

114

Novartis Investigative Site

Rostock, Germany, 18057

Completed

115

Novartis Investigative Site

Rüdersdorf, Germany, 15562

Active, Not Recruiting

116

Novartis Investigative Site

Rülzheim, Germany, 76761

Actively Recruiting

117

Novartis Investigative Site

Salzatal, Germany, 06198

Actively Recruiting

118

Novartis Investigative Site

Schneverdingen, Germany, 29640

Actively Recruiting

119

Novartis Investigative Site

Siegen, Germany, 57076

Active, Not Recruiting

120

Novartis Investigative Site

Siegen, Germany, 57076

Actively Recruiting

121

Novartis Investigative Site

Stadtroda, Germany, 07646

Actively Recruiting

122

Novartis Investigative Site

Stuttgart, Germany, 70174

Active, Not Recruiting

123

Novartis Investigative Site

Stuttgart, Germany, 70176

Actively Recruiting

124

Novartis Investigative Site

Stuttgart, Germany, 70182

Completed

125

Novartis Investigative Site

Tirschenreuth, Germany, 95643

Actively Recruiting

126

Novartis Investigative Site

Trier, Germany, 54292

Actively Recruiting

127

Novartis Investigative Site

Tübingen, Germany, 72076

Actively Recruiting

128

Novartis Investigative Site

Velbert, Germany, 42551

Actively Recruiting

129

Novartis Investigative Site

Weil der Stadt, Germany, 71263

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

An Open-label, Single-arm Study to Evaluate Pharmacokinetics...

Relapsing Multiple Sclerosis

Actively Recruiting

17 locations

A Post-marketing Study Evaluating the Presence and Concentra...

Relapsing Multiple Sclerosis

Actively Recruiting

5 locations

REal World ExperieNce With BRIUMVI4 (Ublituximab-xiiy) Trea...

Relapsing Multiple Sclerosis

Actively Recruiting

88 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here